Marker Therapeutics Inc (MRKR)

Marker Therapeutics (MRKR) Income Statement


Marker Therapeutics Income Statement

Last quarter (Q2 2023), Marker Therapeutics's total revenue was $762.66K, an increase of Infinity% from the same quarter last year. In Q2, Marker Therapeutics's net income was $2.52M. See Marker Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 7.02M$ 9.01M$ 1.24M$ 466.79K$ 213.19K$ 205.99K
Cost of Revenue
Gross Profit
$ 762.66K-----
Operating Expense
$ 17.49M$ -38.96M$ -40.72M$ 29.35M$ 22.74M$ 148.38M
Operating Income
$ -28.10M$ -38.96M$ -40.72M$ -28.89M$ -22.53M$ -148.17M
Net Non Operating Interest Income Expense
$ 328.89K$ 248.06K$ 5.70K$ 148.74K$ 1.08M$ 253.72K
Other Income Expense
$ -9.80M$ -9.01M$ -1.24M$ 31.00K$ 18.00K$ -40.00K
Pretax Income
$ -17.97M$ -29.70M$ -39.47M$ -28.71M$ -21.43M$ -147.96M
Tax Provision
$ -1.02M$ -1.02M$ -103.00K---
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -11.47M$ -29.93M$ -41.88M$ -28.71M$ -21.43M$ -147.96M
Basic EPS
$ -4.07$ -3.58$ -5.47$ -0.61$ -0.47$ -7.75
Diluted EPS
$ -4.07$ -3.58$ -5.47$ -0.61$ -0.47$ -7.75
Basic Average Shares
$ 34.23M$ 8.35M$ 7.65M$ 47.04M$ 45.59M$ 19.09M
Diluted Average Shares
$ 34.23M$ 8.35M$ 7.65M$ 47.04M$ 45.59M$ 19.09M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 17.49M$ -38.96M$ -40.72M$ 29.35M$ 22.74M$ 148.38M
Net Income From Continuing And Discontinued Operation
$ -11.47M$ -29.93M$ -41.88M$ -28.71M$ -21.43M$ -147.96M
Normalized Income
$ -9.26M--$ -28.74M$ -21.45M$ -147.92M
Interest Expense
$ -18.18M$ -29.70M$ -39.47M$ -28.89M$ -22.53M$ -148.17M
$ -16.18M$ -26.02M$ -36.31M$ -27.81M$ -22.24M$ -148.17M
Currency in USD

Marker Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis